Cystic fibrosis antibiotic dosing: Difference between revisions
From IDWiki
(Imported from text file) |
No edit summary |
||
(One intermediate revision by the same user not shown) | |||
Line 1: | Line 1: | ||
{| class="wikitable sortable" |
|||
{| |
|||
! Medication |
! Medication |
||
!Coverage |
|||
! Dose |
! Dose |
||
! Frequency |
|||
! Home IV |
|||
|- |
|- |
||
| Aztreonam |
| [[Aztreonam]] |
||
|[[Burkholderia cepacia]], [[Pseudomonas aeruginosa]] |
|||
⚫ | |||
| q8h |
| 2 g IV q8h |
||
| no |
|||
|- |
|- |
||
| Cefazolin |
| [[Cefazolin]] |
||
|[[Staphylococcus aureus]] |
|||
| 2 g |
|||
| q8h |
| 2 g IV q8h |
||
| yes |
|||
|- |
|- |
||
| Cefipime |
| [[Cefipime]] |
||
|[[Burkholderia cepacia]], [[Pseudomonas aeruginosa]] |
|||
| 2 g |
|||
| q8h |
| 2 g IV q8h |
||
| yes |
|||
|- |
|- |
||
| Ceftazidime |
| [[Ceftazidime]] |
||
|[[Achromobacter]], [[Burkholderia cepacia]], [[Pseudomonas aeruginosa]] |
|||
| 2 g |
|||
| 2-3 g IV q6-8h (max 12 g/day) |
|||
| q8h |
|||
| yes |
|||
|- |
|- |
||
|[[Ceftazidime-avibactam]] |
|||
⚫ | |||
|[[Pseudomonas aeruginosa]] |
|||
| 500 mg to 1 g |
|||
|2.5 g IV q8h |
|||
| q6h |
|||
| at SMH |
|||
|- |
|- |
||
⚫ | |||
⚫ | |||
|[[Achromobacter]], [[Burkholderia cepacia]] |
|||
| 400 mg |
|||
| 12.5-25 mg/kg/dose IV q6h (max 1g/dose) with drug monitoring to target peak 10-20 mcg/mL and trough 5-10 mcg/mL |
|||
| q8h |
|||
| yes |
|||
|- |
|- |
||
⚫ | |||
⚫ | |||
|[[Achromobacter]], [[Pseudomonas aeruginosa]] |
|||
| 2 g |
|||
| 400 mg IV q8h or 750 mg p.o. BID to TID |
|||
| q6h |
|||
| yes |
|||
|- |
|- |
||
⚫ | |||
⚫ | |||
|[[Staphylococcus aureus]] |
|||
| 75 mg |
|||
| 1-2 g IV q6h |
|||
| q8-12h |
|||
| yes |
|||
|- |
|- |
||
⚫ | |||
⚫ | |||
|[[Achromobacter]], [[Pseudomonas aeruginosa]] |
|||
| 2 g |
|||
| 2.5-5 mg/kg/day divided q8-12h (max 5 mg/kg/day) |
|||
| q8h |
|||
| CADD pump |
|||
|- |
|- |
||
⚫ | |||
| Pip/tazo |
|||
|[[Achromobacter]], [[Burkholderia cepacia]], [[Pseudomonas aeruginosa]] |
|||
⚫ | |||
⚫ | |||
| q6-8h |
|||
| yes |
|||
|- |
|- |
||
| [[Piperacillin/tazobactam]] |
|||
⚫ | |||
|[[Achromobacter]], [[Pseudomonas aeruginosa]] |
|||
⚫ | |||
⚫ | |||
| q12h |
|||
| no |
|||
|- |
|- |
||
⚫ | |||
⚫ | |||
|[[Achromobacter]], [[MRSA]], [[NTM]], [[Stenotrophomonas maltophilia]] |
|||
| 10 mg/kg |
|||
⚫ | |||
| q24h |
|||
| yes |
|||
|- |
|- |
||
⚫ | |||
⚫ | |||
|[[Pseudomonas aeruginosa]] |
|||
| 1 g |
|||
| 10 mg/kg/dose IV q24h with drug monitoring to target peak 20-40 mg/L and trough <1 mg/L |
|||
| q8h |
|||
|- |
|||
| yes |
|||
⚫ | |||
|[[MRSA]] |
|||
| 15-20 mg/kg/dose IV q8-12h to target trough 15-20 mg/L; or 15-20 mg/kg IV load then 30-40 mg/kg/day (max 60 mg/kg/day) IV continuous infusion, target steady state level 20-25 mg/L |
|||
|} |
|} |
||
Source: [https://www.cysticfibrosis.ca/uploads/Antibiotic%20Dosing%20Guideline%20Aug%202021.pdf CF Canada] |
|||
'''Source:''' St. Michael's Hospital |
|||
[[Category:Infectious diseases]] |
[[Category:Infectious diseases]] |
Latest revision as of 15:29, 20 June 2023
Medication | Coverage | Dose |
---|---|---|
Aztreonam | Burkholderia cepacia, Pseudomonas aeruginosa | 2 g IV q8h |
Cefazolin | Staphylococcus aureus | 2 g IV q8h |
Cefipime | Burkholderia cepacia, Pseudomonas aeruginosa | 2 g IV q8h |
Ceftazidime | Achromobacter, Burkholderia cepacia, Pseudomonas aeruginosa | 2-3 g IV q6-8h (max 12 g/day) |
Ceftazidime-avibactam | Pseudomonas aeruginosa | 2.5 g IV q8h |
Chloramphenicol | Achromobacter, Burkholderia cepacia | 12.5-25 mg/kg/dose IV q6h (max 1g/dose) with drug monitoring to target peak 10-20 mcg/mL and trough 5-10 mcg/mL |
Ciprofloxacin | Achromobacter, Pseudomonas aeruginosa | 400 mg IV q8h or 750 mg p.o. BID to TID |
Cloxacillin | Staphylococcus aureus | 1-2 g IV q6h |
Colistin | Achromobacter, Pseudomonas aeruginosa | 2.5-5 mg/kg/day divided q8-12h (max 5 mg/kg/day) |
Meropenem | Achromobacter, Burkholderia cepacia, Pseudomonas aeruginosa | 2 g IV q8h |
Piperacillin/tazobactam | Achromobacter, Pseudomonas aeruginosa | 4.5 g IV q4-6h |
Tigecycline | Achromobacter, MRSA, NTM, Stenotrophomonas maltophilia | 100 mg IV load, then 50 mg IV q12h |
Tobramycin | Pseudomonas aeruginosa | 10 mg/kg/dose IV q24h with drug monitoring to target peak 20-40 mg/L and trough <1 mg/L |
Vancomycin | MRSA | 15-20 mg/kg/dose IV q8-12h to target trough 15-20 mg/L; or 15-20 mg/kg IV load then 30-40 mg/kg/day (max 60 mg/kg/day) IV continuous infusion, target steady state level 20-25 mg/L |
Source: CF Canada